Process & Timing

Arasaka operates on structure. Entry is simple, progression is precise, and timing is governed by readiness — not hype. This page outlines how aligned partners and investors move from first signal to active participation: the gates we cross, the artifacts we exchange, and the cadence you can expect. The objective is continuity: outcomes that endure because they were built deliberately.

As of October 2025 — subject to refinement as our platforms evolve.

Overview — From Signal to Scale

1. Signal:You write to[email protected]with intent and context.
2. Alignment:We confirm philosophical and operational fit; NDA where needed.
3. Positioning:Verified entry into the Continuity Queue; timestamp and code assigned.
4. Design:Co-authored scope (SOW), ethics & safety plan, reversibility and shutdown paths.
5. Pilot:Limited deployment with telemetry, audits, and explicit success/stop criteria.
6. Scale:Licensing or strategic program once all gates are cleared and results are reproducible.

The Continuity Queue

Access is sequenced. Every accepted participant receives an immutable position in the Continuity Queue. The queue governs priority for rejuvenation, modification, and neural-integration releases as they transition from research to controlled deployment, then — after investor cycles complete — to public frameworks.

• Fairness:cryptographic timestamping; position cannot be altered by influence.
• Visibility:private confirmations; no public leaderboards, no theatrics.
• Progression:movement through stages follows safety readiness, not marketing cycles.

Safety & Ethics Gates (G0–G5)

No deployment happens without passing through layered gates. We treat ethics as engineering and safety as design.

• G0 — Intent:statement of purpose; exclusion checks for disallowed use cases.
• G1 — Documentation:NDA, brief, initial risk analysis, data boundary definition.
• G2 — Design:SOW draft, reversibility architecture, provenance & audit plan.
• G3 — Review:internal biosafety board + external reviewer where applicable.
• G4 — Pilot:constrained trial with telemetry, operator training, and shutdown drills.
• G5 — Scale:licensing/strategic program; periodic re-certification and ethics audits.

Reversibility is mandatory. If a system cannot be safely reversed, it does not ship.

Required Artifacts

• NDA / Mutual Confidentiality— minimal, surgical, fast to execute.
• Brief— one page: objective, constraints, minimal proof of need or capability.
• SOW— scope, milestones, data boundaries, success/stop criteria.
• Ethics & Safety Plan— risk classes, oversight model, operator training.
• Reversibility & Shutdown— technical and procedural paths, tested before pilot.
• Custodian Liaison— named contacts for decisions and escalation.

Cadence & Communications

• Response standard:we acknowledge signals quickly and provide a concrete next action.
• Working mode:fewer meetings, more written decisions; artifacts > slides.
• Status packets:concise summaries with telemetry and deltas since last update.
• Escalation:use[PRIORITY]in subject + one sentence of impact and deadline.

Timing — Honest Ranges

Time follows readiness. The ranges below are directional; some steps compress when artifacts are strong and alignment is clear.

• Signal → Alignment:days.
• Alignment → Positioning (queue):days after documentation is complete.
• Design (SOW, safety, reversibility):weeks, depending on scope and jurisdiction.
• Pilot execution:weeks to months with interim checkpoints.
• Scale decision:upon reproducibility and cleared audits.

We refuse artificial deadlines. We ship when the system proves itself, not before.

Typical Scopes

• Rejuvenation (Stage I):targeted gene modulation, cellular repair kinetics, immune recalibration.
• Regeneration (Stage II):tissue scaffolds, organoid support, metabolic stabilization.
• Neural Integration (Stage III):low-latency interfaces, cognition support, continuity backups.
• Biomanufacturing:microfluidics, robotic operators, QC/QA automation, digital twins.
• Governance & Security:provenance, audit trails, ethics consoles, shutdown protocols.

Roles & Responsibilities

• Arasaka Team:design authority, biosafety oversight, operator training, telemetry & audits.
• Participant Team:internal owner, environment readiness, adherence to safety & data boundaries.
• Custodian Liaison:joint decision path, escalation, change control.

Compliance & Jurisdictions

Deployments align with applicable law and standards. Regulated environments may require on-prem or VPC isolation, local approvals, and additional documentation. We decline scopes that cannot meet governance thresholds.

Commercials & Legal

• Pilots:milestone-invoiced; structure defined in SOW; escrow available.
• Licensing:time-bounded rights to specified modules; adaptive royalties tied to realized utility.
• Strategic Programs:co-funded roadmaps, joint steering, periodic re-certification.
• Law & Venue:typically Japan (Tokyo), unless a separate agreement defines otherwise.

Numbers vary by scope; structure is constant: clarity, auditability, reversibility.

Forward-Looking Notes

Timelines and capabilities described here may involve systems still in development. They are forward-looking and subject to change. Nothing on this page is medical advice or an offer of securities. Participation depends on verification, ethics review, and compliance in the relevant jurisdiction.

Enter the Process

One clear signal is enough: who you are, what you need, the smallest proof you can provide, and your willingness to operate under governance. We will respond with a path — or a principled “no.” Both save time.

Contact: [email protected]